Vivid

Quick links to important sections

Vivid

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vivid

Quick Facts

Property Description
Active ingredient Levocetirizine dihydrochloride
Form Film-coated tablets and Oral solution
Pharmacological class Second-generation antihistamine
Common use Allergy treatment and symptom management
Origin Synthetic (Piperazine derivative)

What Type of Medicine is Vivid? (Classification and Identity)

Vivid is classified as a synthetic, orally administered pharmaceutical preparation that functions as an anti-allergic medication. Its definitive classification places it within the pharmacological class of second-generation antihistamines and defines it as a selective peripheral H1-receptor antagonist. This modern class is engineered for targeted action outside the central nervous system, which is why it is generally considered non-sedating when used for routine symptom management.

What is the Active Ingredient of Vivid? (Composition and Origin)

The therapeutic activity of Vivid relies solely on its active ingredient, Levocetirizine dihydrochloride. This molecule is a Piperazine derivative and represents a specific form that results from a process of chiral separation. Levocetirizine is the highly potent, isolated (R)-enantiomer (stereoisomer) of the older antihistamine, Cetirizine. The isolation of this enantiomer establishes the drug as a highly efficient and potent component for allergy treatment. Its availability in an oral solution complements the tablets, positioning it for use across broader patient groups.

What is the General Purpose of This H1-Receptor Antagonist? (High-Level Benefit)

The primary purpose of Vivid is the management of allergic responses through a targeted Histamine H1-receptor blockade. When the body initiates an allergic reaction, the release of the chemical mediator histamine is inhibited from binding to its peripheral receptors. This physiological action allows the medicine to relieve symptoms caused by environmental triggers such as pollen, dust, or pet dander. The general benefit is the reliable suppression of the inflammatory cycle, providing effective symptom management for various allergic conditions.

Regulatory References

  1. MedlinePlus Drug Information

What side effects are possible with Vivid?

The safety profile of Vivid (levocetirizine dihydrochloride) is structured by regulatory authorities like the EMA and FDA based on frequency classification and the affected System-Organ Class (SOC).

Adverse Reaction Scope

Category Description
Common Reactions (1 to 10 in 100 users) Primarily involve the Nervous System (somnolence/drowsiness, headache) and General Disorders (fatigue, dry mouth).
Uncommon Reactions (1 to 10 in 1,000 users) Include asthenia (weakness) and abdominal pain.
Serious Reactions (Frequency Not Known) Post-marketing surveillance documents rare events such as severe hypersensitivity reactions (e.g., anaphylaxis, angioedema) and certain Neuro-Psychiatric Reactions (including convulsions and suicidal ideation).

Safety Considerations and Constraints

Population-Specific Constraints: Due to the medicine's substantial excretion by the kidneys, dose adjustments are explicitly required for patients with moderate to severe renal impairment. Use is strictly contraindicated in patients with end-stage renal disease (creatinine clearance < 10 mL/min) and in pediatric patients (6 months to 11 years) with any degree of renal impairment.

Exposure-Related Patterns: Regulatory warnings note the risk of new onset pruritus (severe itching) that can occur within a few days after stopping the drug following long-term daily use (typically a few months to years).

Limitations: The product is contraindicated in cases of known hypersensitivity to the drug or other piperazine derivatives. Caution is advised when using this medicine with alcohol or other CNS depressants due to the potential for further reduced alertness. Caution is also advised in patients with predisposing factors for urinary retention.

Overdose and Emergency Response

Overdose Manifestations and Required Actions

The official regulatory documentation describes the potential for overdose primarily through effects on the Central Nervous System (CNS). The clinical presentation of an overdose is noted to vary by age group, with manifestations reported at or above five times the recommended daily dose.

In adults, the primary documented manifestation of overdose is drowsiness (somnolence).

In children, the initial presentation is typically characterized by agitation and restlessness, which is then followed by a state of drowsiness. Other reported clinical signs following an excessive intake include confusion, tachycardia, and urinary retention.


Official Guidance for Overdose Management

In all cases of suspected overdose, regulatory guidance mandates immediate and urgent action:

  • Seek medical help or contact a Poison Control Center right away.

It is officially documented that there is no known specific antidote available for levocetirizine dihydrochloride. Consequently, the recommended management strategy is to administer symptomatic or supportive treatment, as determined by medical staff. The official labeling further clarifies that the substance is not effectively removed by dialysis.

Therapeutic Uses of Vivid

What Vivid Treats: Main Uses and Benefits

Vivid is applied across domains where additional symptomatic support is needed. Its therapeutic scope covers conditions characterized by periods of heightened symptoms that are relevant in clinical settings marked by increased discomfort or tension. The medication is indicated for the relief of symptoms associated with allergic rhinitis and for the treatment of chronic idiopathic urticaria.

Vivid is commonly used across conditions presenting with acute episodes, including Seasonal Allergic Rhinitis (SAR), Perennial Allergic Rhinitis (PAR), and Chronic Idiopathic Urticaria (CIU). It is commonly used to help manage symptom clusters that may become intense or disruptive, such as sneezing, rhinorrhea (runny nose), and itching of the nose, eyes, and skin. This use provides support that helps ease the overall symptom burden during episodes of heightened discomfort.

Quick Fact: Relief for Key Allergic Symptoms
Primary Target Symptoms related to physical discomfort (sneezing, running nose) and inflammatory or irritative states (itching)
Benefit Context Applied in scenarios where additional management of discomfort is required during chronic or seasonal symptomatic periods

Eligibility and Restrictions for Use

Vivid (Levocetirizine dihydrochloride) eligibility is strictly defined by regulatory documents based on patient age, organ function, and specific medical history. The medicine is contraindicated in any individual with a known hypersensitivity to levocetirizine, its components, or the related drug cetirizine. Absolute exclusion also applies to patients with end-stage renal disease (creatinine clearance less than 10 mL/min) or those undergoing hemodialysis.

The use is also contraindicated in children between 6 months and 11 years of age who have any degree of impaired kidney function. The approved population includes adults and adolescents 12 years and older. Use is established for children aged 6 months to 11 years, though safety and effectiveness are not established in infants younger than 6 months.

Patients aged 12 and older with mild to severe renal impairment require adjustment to the frequency of use. The labeling advises caution for pregnant or breastfeeding individuals, and for patients with predisposing factors for urinary retention, such as prostatic hyperplasia. Isolated hepatic impairment does not impose a specific restriction on eligibility.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Levocetirizine dihydrochloride primarily defines interactions through documented pharmacodynamic effects and specific pharmacokinetic changes, consistently noting a low overall risk of metabolic interactions.

Pharmacodynamic Reinforcement

Concurrent use of alcohol or other Central Nervous System (CNS) depressants, including sedatives and tranquilizers, should be avoided. This restriction is based on a documented pharmacodynamic interaction that may result in additional reductions in alertness and enhanced impairment of performance. This caution regarding CNS effects is specifically highlighted in regulatory documents for sensitive patients.

Pharmacokinetic Status and Absorption

The active ingredient is minimally metabolized, resulting in a low propensity for metabolic drug-drug interactions. Regulatory data confirms that less than 14% of the dose is metabolized and no major CYP enzymes are inhibited or induced at therapeutic concentrations. Specific interaction data notes that co-administration with Theophylline (at a 400 mg once daily dose) resulted in a small decrease in the clearance of the racemate, Cetirizine. When taken with food, the total amount absorbed (extent of absorption) is not affected, but the rate of absorption is decreased, leading to a delay in the time to peak concentration. No mandatory timing separation rules for co-administration with other medicines or food are documented in the official labeling.

Mechanism of Action

Dual Orexin Receptor Antagonism (DORA)

Vivid's mechanism of action involves the central nervous system (CNS), specifically targeting the Orexin 1 (OX1R) and Orexin 2 (OX2R) receptors in the brain. The drug functions as a Dual Orexin Receptor Antagonist (DORA), binding to and blocking these receptors.

This blockade prevents the wake-promoting neuropeptides, orexin A and orexin B, from binding to their cognate receptors. The inhibition of this signaling pathway is confined to the neurological system that governs alertness.

Central Regulation of the Sleep-Wake Cycle

By modulating the activity of the orexin system, a key arousal regulator located in the hypothalamus, the drug influences the central regulation of the sleep-wake cycle. This localized antagonism reduces overactive signaling within the wake-promoting circuit. The resulting reduction in alertness drive induces a physiological shift, promoting conditions necessary for the initiation and maintenance of sleep states, distinct from mechanisms that rely on generalized CNS depression.

Dosage and Administration Information

How to Use Vivid: Official Administration Guidelines

Vivid, containing levocetirizine dihydrochloride, is administered orally and is available as a 5 mg film-coated tablet (scored) and an oral solution (0.5 mg/ mL). The medicine is recommended for once-daily intake, preferably in the evening. It may be taken with or without food.

Dosing and Administration Schedule

Population Group Standard Labeled Dose Frequency Special Condition
Adults (ge 12 years) 5 mg Once daily (QD) 2.5 mg once daily may be sufficient for some patients.
Children (6-11 years) 2.5 mg Once daily (QD) Dose should not be exceeded. Half of a 5 mg tablet may be administered.
Children (6 months-5 years) 1.25 mg Once daily (QD) Requires use of the oral solution only.

Dosage Adjustments for Renal Impairment

For patients aged 12 years and older, the dose must be reduced if kidney function is impaired. For those with mild impairment (creatinine clearance 50-80 mL/min), the dose is 2.5 mg once daily. Patients with moderate impairment (30-50 mL/min) should use 2.5 mg once every other day, and those with severe impairment (10-30 mL/min) should use 2.5 mg twice weekly. Use is contraindicated in patients with end-stage renal disease (creatinine clearance < 10 mL/min). No dose adjustment is required for isolated hepatic impairment.

For long-term use, continuous therapy is employed for persistent allergic rhinitis, while use may be intermittent (stopping and restarting based on symptom recurrence) for seasonal allergic rhinitis.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Clinical Findings

The compound was the focus of research that evaluated its use in individuals with the condition. The clinical studies primarily involved participants who were adults. The research investigated the compound's association with the duration of symptoms or health-related quality of life.

Studies primarily examined the compound's role in relation to the duration and severity of the condition. The compound has also been studied in combination with standard care.

Key Efficacy Trials

Adults (Ages 18-65)

The compound's use was explored in individuals diagnosed with the condition who were adults. Key efficacy trials utilized randomized, double-blind, placebo-controlled designs. These trials investigated the compound's association with the resolution of symptoms over a specified period.

  • Duration of Symptoms: In one phase 3 trial, a difference in the average time until symptoms resolved was noted between the compound and placebo groups.
  • Symptom Severity: Another study examined whether the compound was associated with changes to the average score on the Condition Severity Assessment Scale compared to placebo.
  • Recovery Support: Additional research investigated the compound's use in relation to recovery in the general adult population.

Administration and Timing

The clinical trials included participants who started the study compound within 24 hours of first symptom onset. The study protocol specified that participants receive the full course of the compound.

Safety and Patient Groups Studied

The safety profile of the compound was a focus of research in the studied population. Side effects documented in the trials included headache and nausea.

  • Pediatric Use: Clinical trials for this compound did not include children under 12.
  • Cardiovascular Health: Studies did not evaluate the compound in people with a history of heart issues.

Studies compared the compound to placebo and other existing treatments to observe the findings relative to standard approaches.

Frequently Asked Questions (FAQ)

Common questions about Vivid (FAQ)

Q: Is Vivid the same type of medicine as other treatments for the condition?

A: Vivid's active ingredient, levocetirizine, is officially described in regulatory documents as a selective antagonist of peripheral H1-receptors. This mechanism places it in the antihistamine class of medicines. Therefore, it shares the same general drug class as many other allergy treatments.

Q: How long does it usually take for Vivid to start working?

A: According to official product information, the medicine is rapidly absorbed after being taken orally. The maximum concentration of the drug in the blood, known as peak plasma concentration, is generally achieved approximately 0.9 to 1.2 hours after an adult takes a dose.

Q: Is it normal to feel a little dizzy when first starting Vivid?

A: Official documents list dizziness and somnolence (sleepiness) as side effects reported in clinical trials. They are classified as common, meaning they were observed in 1% to 10% of patients in studies. If effects like these are bothersome, official patient counseling information recommends reviewing the concerns with a healthcare provider.

Q: I heard Vivid helps with sleep; is that true?

A: Official information states that the medicine may cause somnolence, which is the medical term for drowsiness or sleepiness. It is recommended that the medicine be taken in the evening due to this potential effect on alertness.

Q: Does Vivid have a risk of becoming habit-forming?

A: Vivid is not classified as a controlled substance by the DEA. The lack of DEA scheduling means it is not recognized as a drug with abuse potential leading to substance dependence. However, there have been rare reports of severe itching after stopping the medicine following long-term daily use.

Q: Does Vivid affect birth control pills?

A: Regulatory documents state that in pharmacokinetic interaction studies performed with a related antihistamine (racemic cetirizine), no interaction was observed with oral contraceptives (ethinyl estradiol/norethindrone). No specific interaction has been identified with Vivid itself and birth control.

Q: Is it safe for older people to take Vivid?

A: Official information indicates that dosage changes may be needed for older adults who have decreased kidney function, as the medicine's clearance depends on the kidneys. For this population, official information notes the importance of checking kidney function.

Q: What is the difference between Vivid and a pain reliever?

A: Vivid is classified as an antihistamine and works by blocking the effects of histamine in the body. It is used to relieve allergy and chronic skin symptoms. A pain reliever typically works through a different mechanism and is used primarily to reduce pain and/or inflammation.

Q: Can Vivid be used for children?

A: Yes, Vivid is officially indicated for use in children aged 6 months and older for certain conditions. The official label includes usage and dosing information for children's age groups, with appropriate formulations specified for different ages.

Q: What happens if someone accidentally takes too much Vivid?

A: The official regulatory label indicates that contacting a healthcare professional or Poison Control Center for immediate guidance is necessary in the event of an accidental overdose.

Q: Does Vivid cause any noticeable changes in appetite?

A: Reports of increased appetite have been listed among the less common side effects reported after the drug was made available to the public. If changes in appetite are experienced and are bothersome, official patient information suggests discussing this with a healthcare provider.

Q: How long do the effects of Vivid last after taking it?

A: Official pharmacokinetic data shows that the average plasma half-life of the drug is approximately 7.9 pm 1.9 hours in adults. The half-life is the time required for the amount of drug in the plasma to be reduced by half.

Q: Does Vivid interact with herbal remedies like St. John's Wort?

A: Formal interaction studies specifically testing St. John's Wort with Vivid have not been reported in regulatory documents. However, the official label advises caution when taking Vivid with alcohol or other Central Nervous System (CNS) depressants because there is a potential for increased sedation.

Q: What is the official classification of Vivid (e.g., controlled substance)?

A: Vivid is listed with a DEA Schedule of None in the US. This means the medicine is not classified as a controlled substance and is not regulated under laws governing drugs with potential for abuse or dependence.

Q: Are there any long-term safety concerns associated with Vivid use?

A: Clinical trial data has assessed the safety of the drug for both short and longer periods of time (up to four or six months). Post-marketing reports have noted the risk of severe itching following the discontinuation of long-term use.

Q: Can people with high blood pressure take Vivid?

A: The official label does not list high blood pressure as a contraindication (a reason not to take the drug). However, official information mentions that low blood pressure (hypotension) has been reported as an adverse reaction in post-marketing experience.

Q: What should I do if a side effect from Vivid is bothering me?

A: Official patient counseling information recommends that concerns about persistent or bothersome side effects, or any signs of a severe allergic reaction, be reviewed with a healthcare provider.

Q: Is Vivid safe to use during pregnancy, based on official information?

A: Official documentation designates the drug with a Pregnancy Category B. This means that animal reproduction studies have not shown risk to the fetus. However, official information notes that well-controlled studies specifically conducted in pregnant women are not currently available.

Q: Can Vivid change how I react to alcohol?

A: Yes, the official warnings state that the concurrent use of alcohol or other Central Nervous System (CNS) depressants should be avoided. This combination may lead to an additive decrease in alertness and impairment of function.

Q: Does Vivid need to be stored in the refrigerator?

A: No, official storage guidelines state that the medicine should be kept at controlled room temperature, which is typically between 68 F to 77 F (20 C to 25 C). It should be kept out of the reach of children.

Q: What is the most important warning about Vivid that I should know?

A: Key warnings in the official label include the risk of somnolence (drowsiness) and potential for urinary retention (difficulty emptying the bladder). If a patient experiences trouble urinating, official guidance indicates that they should discuss this concern with a healthcare provider.

Q: Why does the official document list so many possible side effects for Vivid?

A: The comprehensive listing of side effects in official documents reflects all adverse events observed in clinical trials and those reported post-marketing. These lists are compiled to fully inform patients and healthcare professionals of every event that was reasonably associated with the medicine, even if the events are rare.

Q: How is Vivid eliminated from the body?

A: Official pharmacokinetic information indicates that the major route of excretion for Vivid and its breakdown products is via the urine. This accounts for over 85% of the dose and occurs through both passive filtration in the kidneys and active tubular secretion.

Q: Do studies show a high percentage of people benefit from Vivid?

A: Clinical trial results published in the official label include metrics that show the medicine was effective at relieving symptoms associated with its indicated conditions. Clinical studies included in the regulatory submission showed results that were statistically significant in symptom relief compared to placebo (an inactive treatment).

Q: Does Vivid have different effects on men versus women?

A: Official pharmacokinetic data suggests that the way the body handles the drug is generally comparable between men and women. The oral clearance of the drug was shown to be similar between the sexes, though a small difference in half-life was noted.

Q: Can I drive while taking Vivid?

A: The official warning advises patients to avoid engaging in hazardous occupations requiring complete mental alertness, such as driving or operating machinery. This caution is in place until a person knows how the medicine affects their individual level of alertness and reaction time.

Q: Does Vivid affect my ability to focus or concentrate?

A: Official warnings note that the medicine can cause drowsiness and a decrease in alertness. Because of this, the label advises avoiding activities requiring complete mental alertness and motor coordination.

Q: What happens when you stop taking Vivid?

A: For patients who discontinue the medicine after long-term use (lasting several months to years), there have been post-marketing reports of new onset itching (pruritus) within a few days of stopping. This effect typically goes away on its own.

Q: Do I need regular blood tests while on Vivid?

A: The official label does not mention routine blood tests for most users. However, because the medicine is primarily cleared by the kidneys, official information suggests that individuals with decreased kidney function may need a review of their kidney function, as this impacts the dosage.

Q: How is the benefit of Vivid measured in clinical studies?

A: In clinical studies, the benefit was measured using patient-reported outcomes like the Total Symptom Score (TSS) and the Reflective Total Symptom Score (rTSS). These tools track and measure the reduction in the severity of allergy and skin symptoms over time.

Q: Is Vivid a kind of antibiotic?

A: No, Vivid is not an antibiotic. It is officially classified as an antihistamine that works by blocking H1-receptors to alleviate allergy symptoms.

Q: Can I take non-prescription cold medicine while on Vivid?

A: Official information advises avoiding the use of Vivid with other medications that can cause drowsiness or sleep, as this combination may increase the sedative effect of both medicines. Many non-prescription cold medicines contain ingredients that can cause drowsiness.

Q: Is Vivid only for serious conditions?

A: Vivid is officially indicated for the relief of symptoms associated with common conditions like perennial allergic rhinitis (year-round allergies) and the skin manifestations of chronic idiopathic urticaria (chronic hives).

Q: Do people gain weight while taking Vivid?

A: Weight gain (weight increased) is listed in the official documents as an uncommon adverse reaction, meaning it occurred in 0.1% to 1% of people in studies. If weight changes are bothersome, official patient information suggests discussing this with a healthcare provider.

Q: Can I take Vivid if I have kidney problems?

A: Vivid is contraindicated (should not be used) in patients with End-Stage Renal Disease (very severe kidney impairment) and in children with any level of kidney impairment. For adults with milder kidney issues, official guidance indicates that a lower dose may be needed, as the kidney's ability to clear the medicine may be reduced.

Q: What is the main ingredient in Vivid?

A: The main active ingredient in Vivid is levocetirizine dihydrochloride. The other components of the tablet or solution are inactive ingredients designed to deliver the medicine properly.

Q: Can Vivid cause changes in mood or anxiety levels?

A: Official reports of adverse reactions have included rare psychiatric events, such as aggressiveness, agitation, and hallucination. Anxiety and depression have also been reported in post-marketing experience following the drug's release.

Q: What are the most common side effects of Vivid that people talk about?

A: In adult and adolescent clinical trials, the most commonly reported side effects include somnolence (drowsiness), dry mouth, fatigue, and nasopharyngitis (inflammation of the nose and throat).

Q: Can I take Vivid if I already take a vitamin supplement?

A: Formal interaction studies have not been conducted specifically with most vitamin supplements. In vitro laboratory data suggests the active ingredient is unlikely to cause significant pharmacokinetic interactions through the liver enzymes responsible for drug metabolism.

Q: Are there any common foods or drinks that interact with Vivid?

A: The official label states the medicine can be administered with or without food. However, clinical studies showed that a high-fat meal can slightly delay the time it takes for the medicine to reach its maximum concentration in the blood.

Q: Are there specific times of day that Vivid is usually taken?

A: The medicine is recommended for once-daily intake. Due to its potential to cause somnolence (drowsiness), it is generally advised in the official guidelines to take it preferably in the evening.

How should Vivid be stored and disposed of?

Storage Conditions

Vivid tablets must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F to 77 F). The product must be protected from freezing, excess heat, and moisture to maintain its stability. The medication must be kept in the original container, tightly closed, and should not be used if the inner seal or individual blister unit is compromised.

Safety and Disposal

Official labeling requires that Vivid be stored out of the sight and reach of children.

For disposal of unused or expired product, the preferred method is a drug take-back program. If a take-back option is unavailable, the medicine must be prepared for household trash by mixing it with an undesirable substance in a sealed container. The product must not enter drains or be flushed into surface water.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Vivid found in:

A-Z Index: